je.st
news
Mylan: Outperformed S&P 500 Since June, And Shows No Signs Of Slowing
2015-01-22 16:03:15| Biotech - Topix.net
Mylan has shown alpha returns over the past year, beating the S&P 500 by approximately 4% in the past four months. The outlook for the drug device combination products industry is expected to grow at a CAGR rate of 7.9% through to 2019.
Tags: of
june
shows
signs
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||